These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 27705947)
1. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis. Yang CH; Wang Y; Sims M; Cai C; He P; Yue J; Cheng J; Boop FA; Pfeffer SR; Pfeffer LM Oncotarget; 2016 Dec; 7(51):84017-84029. PubMed ID: 27705947 [TBL] [Abstract][Full Text] [Related]
2. Metformin treatment reduces temozolomide resistance of glioblastoma cells. Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206 [TBL] [Abstract][Full Text] [Related]
3. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-1 suppresses glioblastoma in preclinical models by targeting fibronectin. Yang CH; Wang Y; Sims M; Cai C; Pfeffer LM Cancer Lett; 2019 Nov; 465():59-67. PubMed ID: 31491450 [TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. Chakrabarti M; Ray SK Apoptosis; 2016 Mar; 21(3):312-28. PubMed ID: 26573275 [TBL] [Abstract][Full Text] [Related]
6. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3. Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931 [TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
8. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000 [TBL] [Abstract][Full Text] [Related]
9. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Yao Y; Ma J; Xue Y; Wang P; Li Z; Liu J; Chen L; Xi Z; Teng H; Wang Z; Li Z; Liu Y Cancer Lett; 2015 Apr; 359(1):75-86. PubMed ID: 25578780 [TBL] [Abstract][Full Text] [Related]
10. miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA. Qiao W; Guo B; Zhou H; Xu W; Chen Y; Liang Y; Dong B Biochem Biophys Res Commun; 2017 Apr; 486(1):43-48. PubMed ID: 28242198 [TBL] [Abstract][Full Text] [Related]
11. MiR‑203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting Survivin. Xu D; Wang Q; An Y; Xu L Mol Med Rep; 2013 Aug; 8(2):379-84. PubMed ID: 23732815 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes. Liu F; Gong J; Huang W; Wang Z; Wang M; Yang J; Wu C; Wu Z; Han B Oncogene; 2014 Oct; 33(40):4813-22. PubMed ID: 24166509 [TBL] [Abstract][Full Text] [Related]
13. Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells. Cheng YC; Tsai WC; Sung YC; Chang HH; Chen Y Cell Physiol Biochem; 2018; 45(2):819-831. PubMed ID: 29414809 [TBL] [Abstract][Full Text] [Related]
14. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397 [TBL] [Abstract][Full Text] [Related]
15. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Gallo-Oller G; Vollmann-Zwerenz A; Meléndez B; Rey JA; Hau P; Dotor J; Castresana JS Cancer Lett; 2016 Oct; 381(1):67-75. PubMed ID: 27473823 [TBL] [Abstract][Full Text] [Related]
16. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. Lulli V; Buccarelli M; Martini M; Signore M; Biffoni M; Giannetti S; Morgante L; Marziali G; Ilari R; Pagliuca A; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L Oncotarget; 2015 Nov; 6(35):37241-56. PubMed ID: 26437223 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9. Liu N; Zhang L; Wang Z; Cheng Y; Zhang P; Wang X; Wen W; Yang H; Liu H; Jin W; Zhang Y; Tu Y Oncotarget; 2017 Mar; 8(12):19244-19254. PubMed ID: 27911279 [TBL] [Abstract][Full Text] [Related]
18. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112 [TBL] [Abstract][Full Text] [Related]
19. Efficient delivery of anti-miR-210 using Tachyplesin, a cell penetrating peptide, for glioblastoma treatment. Jana A; Narula P; Chugh A; Kulshreshtha R Int J Pharm; 2019 Dec; 572():118789. PubMed ID: 31726199 [TBL] [Abstract][Full Text] [Related]
20. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]